CLOs on the Move

Intrexon Corporation

www.dna.com

 
Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.dna.com
  • 1872 Pratt Dr, Ste 1400
    Blacksburg, VA USA 24060
  • Phone: 540.961.0725

Executives

Name Title Contact Details

Similar Companies

Makindus

Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.

Leesville Rehabilitation Hospital

Leesville Rehabilitation Hospital is a Leesville, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Altea Therapeutics Corporation

Altea Therapeutics Corporation is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

St. Mary's Janesville Hospital

St. Mary's Janesville Hospital is a Janesville, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medicenna Therapeutics Corporation

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna`s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna`s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna`s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.